IQVIA Holdings Inc. (NYSE:IQV) Expected to Announce Earnings of $1.85 Per Share


Share on StockTwits

Equities research analysts expect IQVIA Holdings Inc. (NYSE:IQV) to report $1.85 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Nine analysts have made estimates for IQVIA’s earnings. The lowest EPS estimate is $1.82 and the highest is $1.90. IQVIA posted earnings of $1.50 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 23.3%. The firm is scheduled to report its next earnings report on Tuesday, April 27th.

On average, analysts expect that IQVIA will report full-year earnings of $7.96 per share for the current financial year, with EPS estimates ranging from $7.85 to $8.10. For the next year, analysts expect that the business will report earnings of $9.31 per share, with EPS estimates ranging from $8.88 to $10.07. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for IQVIA.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Wednesday, February 10th. The medical research company reported $2.11 EPS for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.11. The firm had revenue of $3.30 billion for the quarter, compared to analyst estimates of $3.14 billion. IQVIA had a return on equity of 18.03% and a net margin of 1.61%. The company’s revenue was up 13.9% on a year-over-year basis. During the same quarter last year, the company earned $1.74 EPS.

A number of equities research analysts have weighed in on the company. Morgan Stanley raised their target price on IQVIA from $205.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 11th. Truist raised their price objective on IQVIA from $197.00 to $235.00 in a report on Thursday, February 11th. Wells Fargo & Company raised their price objective on IQVIA from $205.00 to $230.00 and gave the company an “overweight” rating in a report on Thursday, February 11th. Mizuho raised their target price on IQVIA from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Thursday, February 11th. Finally, Piper Sandler raised their target price on IQVIA from $179.00 to $204.00 and gave the stock a “neutral” rating in a research report on Thursday, February 11th. Three analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $183.67.

In related news, Director John G. Danhakl purchased 63,451 shares of the firm’s stock in a transaction on Wednesday, December 23rd. The shares were acquired at an average price of $176.95 per share, for a total transaction of $11,227,654.45. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 6.00% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. grew its stake in IQVIA by 4.9% in the 4th quarter. BlackRock Inc. now owns 14,826,277 shares of the medical research company’s stock worth $2,656,421,000 after acquiring an additional 688,054 shares in the last quarter. State Street Corp boosted its stake in shares of IQVIA by 1.9% during the third quarter. State Street Corp now owns 8,265,984 shares of the medical research company’s stock valued at $1,302,967,000 after purchasing an additional 157,447 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of IQVIA by 7.9% during the fourth quarter. Alliancebernstein L.P. now owns 6,303,471 shares of the medical research company’s stock valued at $1,129,393,000 after purchasing an additional 461,873 shares in the last quarter. Great West Life Assurance Co. Can boosted its stake in shares of IQVIA by 1,998.8% during the third quarter. Great West Life Assurance Co. Can now owns 3,187,359 shares of the medical research company’s stock valued at $25,138,000 after purchasing an additional 3,035,496 shares in the last quarter. Finally, Morgan Stanley boosted its stake in shares of IQVIA by 19.1% during the fourth quarter. Morgan Stanley now owns 3,020,834 shares of the medical research company’s stock valued at $541,242,000 after purchasing an additional 483,960 shares in the last quarter. Institutional investors own 87.15% of the company’s stock.

Shares of IQV stock traded up $0.70 during trading hours on Tuesday, reaching $190.84. The company’s stock had a trading volume of 45,558 shares, compared to its average volume of 924,720. The firm’s 50 day simple moving average is $186.50 and its 200-day simple moving average is $170.55. The company has a market capitalization of $36.50 billion, a price-to-earnings ratio of 208.95, a PEG ratio of 2.26 and a beta of 1.41. IQVIA has a fifty-two week low of $81.79 and a fifty-two week high of $199.99. The company has a quick ratio of 1.12, a current ratio of 1.12 and a debt-to-equity ratio of 2.00.

IQVIA Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading: What are benefits of a growth and income fund?

Get a free copy of the Zacks research report on IQVIA (IQV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.